NNOX - Earnings call transcript Q4 2023

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, and thank you for standing by. Welcome to the Nanox Fourth Quarter 2023 Earnings Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to Mike Cavanaugh, Investor Relations. Please go ahead.

Mike Cavanaugh

you us thank and morning, for today. joining Good today, Nanox Ltd. Imaging Earlier ended for XXXX. results financial December the released quarter XX, The release is of the currently available on website. the company's Investors section Erez Chief Ran this Officer; call. Meltzer, will morning's Officer, host Daniel, Chief Executive Financial and

activities, to results, Before management assumptions that everyone regulatory manufacturing research this that may and will would and regarding statements and commercialization during to that matters. include risks, expectations statements statements current These development, remind forward-looking not we making in the I get the call started, and like subject based process be company's future. are are and as operations other updated today management's on uncertainties of be financial

of any date. may statements difference but Securities such company's that should include, subsequent a be Commission. cause the with these the not and described as in not Exchange those as limited representing filings to, are upon Factors Therefore, views relied the company's

ordinary shares, non-GAAP profit expenses, of additional loss measures also gross non-GAAP refer revenue, measures non-GAAP non-GAAP gross general with will development We marketing gross non-GAAP expenses research profit, with and non-GAAP our expenses, to being and net press of non-GAAP the is loss and provide to investors. GAAP provided non-GAAP release cost non-GAAP financial A reconciliation margin, differences sales non-GAAP the to primary administrative attributable and to information per certain to share.

over turn to call like to Meltzer. now the I'd that, Erez With

Erez Meltzer

results for and us Thanks, corporate as Mike. today for you And call our financial thank joining always, all update.

January. as early to founder, to of and on will will acknowledge I Ran to lead him our usual, proud the business our gratitude, treatment of outcome. My the a improve lot aspects of of realize longer and minute We making help a a our started, achieve a owe health details like to be get provide we to team than and detection vision seek would all Before Poliakine, to I remarks his better Nanox. we people more bit back in I'm passing accessible medical imaging today take various

we course exciting financial results, As the the first the highlighted the review our I'm by of over progress mission and clear extremely of of and team XXXX, Nanox.ARC our update our FDA made clearance in and validation the quarter share our proud a milestone system, of steps U.S. commercialization. for technology our fourth

I fourth as today's On achievements our in quarter will for of will Nanox. expect well which transformational some focusing call, we as early our be on be year a activities XXXX,

our as the in are the Nanox.ARC raise of of commercial steady is We dedicated increase a and process aiming we in expanding in strategic future U.S. and infrastructure now system plans the Nanox the deployment solution. our Nanox of commercialization are to accelerating awareness of implementation the for

U.S. to advantage the deployment our mission an patient practices that call capabilities, our activities. to Our Nanox.ARC, update but imaging is advanced I'd provides on like with health care. provide accessible elevates start overall through care also with diagnostic an not a solution game-changing only cost-effective

which states, the the Since area. As York the we we as New in at deployment, already launched first then, in U.S. have going have have disclosed is New metropolitan in Jersey, in deployed we across past, the location an U.S. in the X advancement our planned. ARC marking

which the sites bodies. center. have technical diagnostic and and spending system medical imaging Florida, been The Nanox.ARC in patients. states Imaging operation system scan system a training certification at regulatory in Academy, system began Clinical Georgia corresponding from as well begin ARC will to as Jersey, of Kansas, ARC other New serves the and call, today's New the installed XXX centers of As York, several as

these of back and we Day Investors the validated as X the on purposes $XX validate our indeed per is as these is installations initial the per well are As our already around that it assumptions. indicated scan. model deployments, in indication for December, seems to scanning in Based MSaaS of scans one day,

of a infrastructure, of MIS Training at part use Engineers Imaging and Atlanta XXX of establishment site the Program completed training successfully Georgia the the and Woodstock for serves Academy technical the on have Center. at they our As Training technicians the system center as XXX our

coverage. are This another and service to order scale. expand our installation, in with maintenance provider advanced is negotiation We in to prior service

As footprint to we expand across technical our sales States, our we continue the teams. increased U.S. United and

personnel are our being to in planned. our additional team At the generate investment. our a that time, on the judicious expenditure sales additional professional have same extending gradually aim are as recruited the ensure We grow good we hires as about We are U.S. expand to and return continuing and needed network to

sites we that MSaaS can As the the are that utilizing imaging up streams share we ARC model. ramp begun deployment, have scans at the I realizing deployed from U.S. revenue

final the regarding one commercial address U.S. operation to like in aspect I'd our

various As request standard the per Nanox.ARC the on procedures, of future these progress placement has eager submitted units our of you across country. certification expand updated installations. states to the I'm a Nanox to to keep

now Turning world in the to of deployment outside market. the rest of key efforts our the U.S.

March. in installations revenue on deployments we disclosed as of we call, of last generating from the end and our Africa hardware X As had are

University mentioned, Ghana. Ghana have can I we had the Ghana unit now done share Centre installed which of multisite regulatory at and we a previously As clearance. signed a our trial was received of has that which as Limited, part have agreement, in local Medical UGMC, multisite

bit to aiming later I this in describe Nanox.ARC. and We a will are conducting remarks. more the data my in trial trial, detail clinical on generate continuous evidence the

made in country. We presence in Latin the our this has a is offering actively already and system with distributor, cloud-based health other hospitals patient exams which marketing Nanox.CONNECT us the key have remote with in enable with in CONNECT should for a care America. product to the footprint medical product partnered into partner progress and that Nanox recent complementary solution good is partner as has reach which expanding by agreement One a solutions, also be The clinician. equipment Peru-based Peru distribute strong health the local

I distributor partner import you has solution, the also also in the CONNECT can for Nanox.ARC update The X for license preparing the that seeking generating first the to installation. and this our XXXX. that systems. first we is an shipped for continue import have registration anticipate Similar an distributor ARC, the we in will received and to revenues the has sell to also Nanox.CONNECT, also required obtain and Mexico the applied license

to and CONNECT as beginning. being complementary the that ARC it's from marketed gratifying very we the see that have envisioned As a together side comment, I this will say solution very imaging

in will Ran I'd like update to on our more hardware revenues, shortly. details provide an which review

imaging While and for our AI its begun deployment revenues of QX, the have outside generating solutions Nanox the in U.S. generate sales we begun through to of systems. revenue

I'd Nanox base Now update quarter. to an like of provide last AI to in has our which business, client on increase had compared XXX% an

an system future levels have HealthCCS, who installed health calcium, of base proven events. AI-powered cardiac detect We use of an a indicator artery of solution coronary to

Corewell and solution. using a is formerly experience specifically health this Revisiting cardiologists digested in users, partners, population Health, began have and large health the system. radiologists Spectrum, integrated AI from feedback product our upgrade to one and with which in gathered of mid-XXXX our the field the We solution

fully this has received which their been care. of consistently which been feedback positive have for from Corewell a Health, integrated into has standard has extended terms. productive We This partnership additional

than company. Nuance's Precision Many I More Network, activities will on available the of on part XX,XXX are of health and radiologists Nuance's into and for XX% use HealthCCS Nanox started integration PowerScribe of Nuance that that you a reporting. Imaging the solution to internal share the aware bundle. Microsoft can facilities solutions training systems. Health care are has go-live of InterMountain The radiology including process signed and deploy was U.S.

an HealthFLD with in sign hepatic as steatosis, milestone scans. automated, analysis steatotic regulatory by Nanox to liver XXX(k) provides of referred support FDA, disease. CT also that formerly and received intended and routine liver qualitative correlated quantitative for artificial U.S. of we liver of an the is disease, attenuation metabolic the detection associated, when MASLD, nonalcoholic the intelligence clearance achieved software clinicians Administration, month last liver to Drug dysfunction early fatty Food HealthFLD, from another fatty

as which and to general make scans, a is tool traditionally has the routine and proportion was up liver from as a including CT population scans. of medical contrast-enhanced clinical liver to help new valuable candidates assessment for advantages in the doctors been fatty of liver HealthFLD designed AI CT for it a of devices. in HealthFLD difficult HealthFLD innovative the analysis trials decision automated believe of the on NASH. industry the large We solution regulatory to may attenuation assess scans. specifically streamline for therapies deliver diseases, and leadership identification biopharmaceutical our substantial solidifies This to much-needed that software of developer AI clinicians

last We patients fracture the AI-enabled month and in vertebral scan hospitals Health helps tools, conducted version AI up ADOPT clearly findings Services, solution, being the study NHS previous earlier the current intervention enabling than VCF, to the fractures possible patient The Nanox also the announced University's routine NHS, and vertebral shows better with has The HealthOST at CT study, Xx our Oxford with various sites, ADOPT to far which patients that of compression National identify service that from including demonstrated U.K. early average at review solution to more the uses outcomes. existing HealthVCF the compression health national previously ability is identify or data potentially in more national hospitals.

unknown fractures evaluation and AI algorithms previously have treatment. the date, for Nanox identified To compression designated over patients those vertebral and X,XXX with patients has follow-up been

see, of deployment, busy we important solution. but system component very the complete advancing Nanox only not also Nanox.ARC the which AI, of with can you uptake As been an this Nanox is have

on are Varex and our engaged to OEM we multiyear company's partnership, the to last supply agreement Lake tubes. Salt towards now headquarters production year, executive Expanding Turning purchase ensure After future validating the have at advancing design future to and first towards technical imaging tube production teams an issued a the and tube supply adequate in order exploring activity, industrial to manufacturer meetings development. our in actively equipment kickoff of map continue City work road initiatives. OEM-related our

tubes for U.S. with based X After for on collaboration exploring of Nanox.ARC meter. evaluation, security advancing on we chips toward acquisition using the and our and novel agency a applications are progressing. our Additionally, collaboration their technology government

kits, few increasing our coming allowing to weeks. have our will to the received interested delivering Finally, be demonstration the access safety regulation we utilizing created Nanox we recently necessary core our and as and a technologies, the of kit first means in have and containing and a tube awareness parties certifications for meter,

system, the a mass continue production maker Switzerland. as to the recently with due located collaboration as in Regarding chip we announced, commercialization, in planned with scale-up our the

As to indications. used ready. The that chest and and these is patients. finalizing in The I trial trial integrating system comments Nanox.ARC conducting Institutional mentioned being multicenter are the has use Review with enhance are Nanox and Ghana, based in the is states clinical begin The are into to we is approved expanding other scheduled multisite. already goal my of trial, about installed with hospital earlier for the recruitment IRB, systems trials patient shortly, and in Nanox.ARC remaining scanning Board, its

IRB the been is currently under Ghana, has submitted review. In and

The is Beilinson, used an to scan radiology. academic to lung the abnormal patients. institution top of patients conditions that the is and advancement UGMC at being world's being system used Additionally, scan has currently center with in also pioneer medical at Nanox.ARC one

Europe Our pursuit advancing with in is mark in CE notified partnership body. the our of

completed Specifically, regulations, MDR plus we for certificate. a certification XXXXX process the CE recently, notified by medical part as the body the X-day certificates, device audit the ISO of

great MDR reports, The During any were successfully. hundreds without was adverse procedures, presented. records, XXXXX passed success the test of with inspection, passed a ISO test findings. The was proofs, and and example

backlog would pandemic in after formal although the audit, for timely begin, COVID process worldwide process. I which accumulated regulation. regulatory includes applications, review manufacturing to of process of new the the we and are that still note the multiyear manner, a Sometime a examining during through which And proceed the working the bodies expect aspects will application MDR our adjustment

continue we'll necessary as However, the work certification to process process, prioritize our the complete with we partners said, CE are tests along the line. finish bring required with and I well in the to the to

Ran? to now to Ran a over like the I'd of that, call for financial With results. Daniel review turn our

Ran Daniel

comparable comparable $XX.X of quarter the of you, is period. largely period, expenses. net $X.X with The for Thank a of a the settlement million of action in loss quarter fourth goodwill the the is and administrative Erez. We million which the GAAP XXXX, $XX.X connection were general of And million accrual the XXXX in to $XX.X million compared fourth a recorded reported million, the net which decrease impairment with loss which in the in reported class the of due and of of an $X decrease period. . was

in reported period which on period. reported basis the comparable compared fourth XX% basis was of of the was million a million, $X.X to was million, loss Non-GAAP as the XXXX margin approximately gross period $X.X for represents loss basis. for in as was quarter gross GAAP comparable period profit the was $X.X basis. $X.X for GAAP on on million Revenue XX% compared and million a the period, a $X.X on $X.X Revenue million gross gross for to non-GAAP profit non-GAAP a and comparable a the

was a the the the GAAP represents teleradiology in compared to basis a on gross GAAP million profit profit in million $X.X XX% on of a million of basis of profit gross period. margin for as comparable comparable for from $X.X of period on to as $X.X reported basis a million basis with with a period approximately Revenue a on GAAP period, the $X.X revenue reported compared a the XX% gross GAAP which services

the Non-GAAP on period, $X.X $X.X radiologists teleradiology a which reported to The basis XX% the the period XX% as the the to read mainly for due the to margin or which for shifts. on a in million comparable and compared on paid and during weekend margin and the for of profit non-GAAP basis a profit an as to reported incentive of increase approximately gross in overnight in period. -- was company to company's in the compared profit rates gross non-GAAP basis company's million period represents decrease the engage gross a the GAAP in the comparable radiologists non-GAAP is payments, increase payments the cost due in services the to company's

sales solutions the the During $XX,XXX of the its in period, reported to the company $XX,XXX of compared revenue through as in of reported revenue generated the period. amount AI

the and after. first the a fee for HealthCCS an second anniversary fee of AI U.S. sold to of $XX,XXX the in XXXX, Nanox of during of its annual solution IDN of quarter first an year annual the the During $X,XXX and the from first engagement engagement

its the company the stems to revenue During GAAP in sales our Those and system, $XX,XXX, the revenue systems of imaging gross of reported of which sales with and amounted period, from non-GAAP through a and deployment loss generated Africa. deployment a basis. the $XX,XXX XD on

to the $X.X expenses activities. and related sales our marketing comparable expenses decrease reported million of in as in the $X.X due due comparable in million, to development million $X.X was Sales expenses to reported marketing $X.X a million million company's and for decrease period. the were a the were the Research to $X.X period compared period compared decrease in as was period. The mainly The development mainly decrease expenses. to for and

General amount class the period in $X.X million, (sic) action, ] the cost decrease as million compared and $X.X the reported million. the compensation a decrease to largely and were liability our premium settlement expenses decrease million the million SEC a Directors to share-based as a $X.X amount in of the insurance the of a administrative mainly of and period. in result of of the $X.X officers' of due finalization for the of in the investigation the decrease $X.X in and million, in The was comparable million, legal $X.X [ of in amount $X.X expenses

this the against amount $X reported with the period. reversed company $X the $X.X compared in lawsuit for the the Other the income class action period agreement million $X.X since class connection the comparable received action the of the D&O company. was expenses included as period, settlement amount which expense with the million an amount of to in comparable for period insurance lawsuit settlement in million, connection the company the Other in against career by an its reported was for the of million accrual from under in

balance Turning sheet. to our

marketable we XX, million of million, a bank. $XX.X and equivalents, approximately As of cash, and and the ended a loan from cash net securities December property XXXX, $X.X we equipment had restricted quarter had deposits We of million. $XX.X with

million December of gross mainly the was XXXX. shares shares the shareholders The and million of As XX, million direct the proceed compared a agreement. of shares as December approximately X.X of to million shares proceeds under USARAD approximately due $XX.X to X.X purchase of sales XXXX, had warrants, USARAD $XX XX.X of in approximately former issuance and million purchase in to outstanding XX, outstanding, consideration we the shares of stock as ordinary to and increase million of a registered the the offering XXX,XXX of net amendment approximately the XX.X

I will to the With over hand call Erez. back that,

Erez Meltzer

Thank and when to the you Nanox's important since efficient, been once and for stepped years into mission has clearance In use we And to expand imaging in make Nanox CEO support again place. of It your accessible of potentially continued very joining just medical call I I worldwide. our case the the today all for more X year, ARC FDA. here, role. and different came are achieved a FDA with an seeking milestone was this affordable

know we like in local center U.S. deployed today's deep hospital by in ARC CE to We've in X also have as Africa, Israel, in countries numerous in imaging received we use Ghana. the countries for and the commercialization, and systems systems are deployed regulatory extend the clearances now begun systems Union into call, and of and designation the are also pursuing process European of mark We other have [indiscernible]

the we AI strategy years, our across have Over these company. integrated X

provides AI to identify patients achieved FDA initiating help ability solution and disease, X asymptomatic clearances, management. undetected this early we In year, with use to validation clinical the of Nanox leading AI highlight also AI solution. diagnosis chronic our substantial Our and preventative a

We progress even excited for road, and is more been understand very our has but a in tangible long are we this XXXX. progress

demonstration end of we the I this one Wednesday, been of ARC something installed the dynamic demonstrate Before piece many of and a you the X:XX interested if Westwicke have by medical Jersey, imaging attending, beginning is followed On Investor April discussion. you will share, and Union, at are XX, The use Relations I have our Please will news space to New partners anticipating. ICR note be in a.m. last limited. at in is contact that a system, call, roundtable

With again and XXXX year once full and that, quarter investor I thank close. our call at bring you fourth

Operator

Instructions] [Operator

Erez Meltzer

Just before site to session, enhanced the we visualization chest is from updated I clinical Q&A clinical mention sample, cervical have dive example and to radiography. One we note U.S. traditional into the with like the pathologies website compared that spine commercial site. from scan. interesting would In our we U.S. our

study chest only images Nanox.ARC Additionally, visualized while clinical for a can the on this study, in from in you x-ray find trial. clearly CT frankly biopsy. was and the the the the scheduled chest the Beilinson of scan lesion lesion, shows patient And the

a to So it and well. look Q&A. see take as feel free

Operator

Ross come the first Osborn question line Cantor Our will from of Fitzgerald. with

Ross Osborn

progress. the on Congrats

visibility in also how thus far pipeline into with provide many quarter and discuss the has placements of across your off orders? in X would states are XXXX operational systems backlog us deployed with or starting the terms and the fourth So of progressed during U.S. ARC, how you

Erez Meltzer

So indicated the year, Ross, will that we more already details. add we along have

we facilities is we states. say installed have in a how not many manufactured have we thing say just indicated. X So would already that one of in systems have and have clinical that few We systems systems the dozens informed as far, the now The we right installed systems. exactly I

the give that far already to the the and Next, few I been I day, in were that per the dozens and would shipped sold various so next scan, will and dollars you numbers. numbers scans say more meetings, The locations. probably we mention per gave that are

Ran Daniel

systems there's And a of the a -- due number the local Ross, ones gap that of mind registration operated state to between requirement. difference or are that the the commercially between time to since there's installed or you amount the

Ross Osborn

with then adopting has And types what color you centers Understood. of $XX trended their and are maybe utilization ARC, could of on comfort level and thus far, per how provide scan? some

Erez Meltzer

Yes. We can.

medium-sized small we and imaging now. So have medical right centers

And all are I other them do the that else One is of Yes, think them, type of screen yes. thing of of -- the clinical what of all that we can them is areas. I we If indicate big. these them, that's have? most actually

would the have are in Georgia I of yes, And The few orthopedic numbers. a site installations that that's say, and the in other we clinical one centers, is Yes, XXX.

Ross Osborn

in we of about... lastly Got is for economics remind in sale of would terms or given us, be a MSaaS, that's going the it. you and capital us think if And your CONNECT, how then to And MSaaS? whether agreements on it should Peru Mexico

Ran Daniel

Most are that to manner of them ARC. MSaaS know models the the apply in we that -- same

are capital said, do we a of Sometimes, most models. MSaaS as regards model But them CONNECT. sales with to I

Erez Meltzer

Ross, in then In it a we amount countries, the In of sell on charge sell the partial depends decision for system. especially certain few per we make and a also them, scan. to Africa, countries.

have models CONNECT. the on We various

Operator

Cohen the question of Ladenburg next line from Our come with Jeff Thalmann. will

Jeffrey Cohen

up the a Could a you U.S. play talk and out both of follow about you little questions. on anticipate want both us a give to and in sense in how deeper and versus platforms couple ARC of Ross' a did to I OUS? CONNECT scale bit CONNECT those

Erez Meltzer

to Okay. to CONNECT sold the we're going Right it U.S. FDA get the U.S. well. the is in outside now, the going the sell the in being Once CONNECT of as is U.S.,

of are part them America lot CONNECT XX have Israel. And are of in them and in Africa, Latin than We right right now. now a countries more

line system or we of sell. not the beauty the included of sell but in as we what in CONNECT sell extend of the of of products have. equipment, with it expand AI all, First And a we that piece only we is purpose what to bundled CONNECT the was that the

itself. can analyze image the So the system

it used various the there. we systems and Israel were were was Morocco, It in or in behind extreme that field. was that screening them do can twofold. by earthquake example, the when addition, sold the for testing in situations, the buried the field In And in customers in idea also in is you have used

we and the build The we that later imaging get the sometimes AI how CONNECT say is get on, do we the and system that itself. first the the one ARC, or second is we into inclusion

in And terms process it's process. the same CONNECT, the the of of

Sometimes the they the ARC, before just get registration sometimes after the ARC.

very If the examples you few that ARC actually flexible what the in beneficial very well. can is the CONNECT, we in X actually envisioned enable fact before. I complementary and the us, for fact really have fact reemphasize for value and that XXX. are us The are And the model, with CONNECT, to penetrate clinics of take do. that that some the see countries Africa will that the and CONNECT sale, very and of achieved, basically one per of MSaaS hybrid the this the gratifying us model a in were for as CapEx-based we beginning, marketed from adds they terms countries, the the lot the we to scans business are we together these days as it's examples of or that actually X day a above number

Jeffrey Cohen

deployments, maybe and majority is sites to the guess, that sites types clearances of I what of both of CONNECT? Erez, have depending you're anticipate you on ARC a or So saying would lot

Erez Meltzer

ARC. countries the the majority Latin would U.S., CONNECT. like that a rest the that countries to some of use not we be because in say mainly will will than in sell say I of sometimes In would will America it lot see ARC. and the world, CONNECT But would I the more

the there's sign that to as By and access get we we do. was that's to then that get it the Sometimes upon with medical saw CONNECT beginning trying able to were few the a ARC. mission we're ways countries in the the we imaging ourselves various because for preparation way, to took we and

Jeffrey Cohen

And on it. that you comments previous could X,XXX Got Was systems clarify manufacturing? manufactured?

Erez Meltzer

were No, We of have no. a said dozens already no, that few that we manufactured. systems

the you of We installation the cover of now. the few that think if about think are are you availability And more the if in the enabled manufacturing to us items about we a process this of and pace parts, actually doing dozens. right long-lead

don't a remember, not in going U.S. said We make conservative have the a first are second Day, Investors the chance you If impression, to especially a in we we in very approach. that

are we So we the systems, analyzing are installing the data.

adding of improving installation. are We and the process the

We shorten the time able have been install the we systems. to that

negotiating are coverage now better will U.S. the that We another service have company a for right

ability of lot a gained have the from control access We also the or to systems remote.

opening are units. We these the us best to that serve call enable will center

ensure people to the And that of the but not in team, people to professional the course, are are to of doing sales least we personnel. referrals increasing is the and professionally. of standard We be on that it service that that last of exponentially and are and do will the we we'll care, work changes the and number aware additional we continuing are have, recruited in expand our teams and

Jeffrey Cohen

on as far XXXX quarter for first commentary any cetera? revenue sequential et changes, et lastly And it. cetera, us, as Got

Erez Meltzer

Yes.

where all, are first that part So of we I so indication are of gave the far.

be so And the will number growing.

I process are focusing and are share as install. are installation heading. the We that we that as more generating numbers believe to in on well more and where we're we'll the current quarter, we installations more that next of and able to the what's update be And systems scans detailed in revenues, going more

making Right and now, according are to Day. what plan we the according in to exactly Investors progress was the presented

indicate we based conservative that right in and we to ensure what we best on we experience, delivered. imagine, are As you are more now, will be we're can what promise and careful trying much whatever say, we

Operator

next Anthony line from the Our Petrone will Instructions] question [Operator with come Mizuho. of

Anthony Petrone

of Erez, for systems per last mentioned and Maybe, on just some scans are X to and utilization strong Nanox.ARC, doing day. the scan, strong the the year. per year system this early end Congratulations of on start you $XX per

Is utilization? the you and more Nanox.ARC, that XXXX? you Just that orthopedic couple x-ray? scaling it on chest a where in the cases bit scale And to how on seeing expect you're of Just and side? follow-ups. seeing see how use over you which little Are for you seeing a areas have are I'll it on then early

Erez Meltzer

disrespect question. others, great Okay. to the No but

I are day the we and see. actually from days what centers day. X we basically we scans it had built First are had, than installations, more however, of -- are the all, with per and that's that we say people seems early XX imaging that per scans there that which model that, say, professionals but I the who can doing, what would medical we understand in is really

this beginning. So the

terms scan, $XX, of to if dollars this to world. the is you $XX the compared of $XX remember In the rest in the per the

So imaging generated, is is in that code of $XX. radiologists. the And for and the could CPT line the be room for center, the lot U.S. us, reimbursement leaves which and of about the this medical center, for actually a for

the kind So like have the these right respect In following, the skull, FDA. we now right abdomen, Israel, do lot we chest, do a other indications. in we do do clinical that we MSK remind I'd indications, of to Unlike other okay? rest see of we U.S., the world, are the in all numbers Africa, now. With places, to the do that we we in

indications that I XXXX other Our made as comment very beginning. the in in FDA the will include submissions stated

of places, very actually screening, Beilinson have regulation, we I uploaded this examples actually with the cervical indications clinical seems forward original to website pulmonology clinical now, chest work part We and Hospital these of do on, to we because plan. going do. and the us, we and as right for part we example, spine do of not have scan Even that but for are of even of in the careful that Israel, other because we our that more on taking. the it originally than because samples also is that were the the them be based of So cancer we're anticipated. FDA, all move some

Anthony Petrone

artery running. getting How do And we looks it's have And That's on think at artery patients see think next actually of solutions being InterMountain, follow-ups the and and with and of over in XXXX? for like analyzed coronary calcification over volume helpful. this specifically with will CCS I evolves? just the cases about Health many in disease, you of years see a it next how they're months progressing there, you It's InterMountain that few when InterMountain. collaboration do as trend seeing few how terms HealthCCS AI it deployed in coronary couple the and up we'll

Erez Meltzer

Okay.

seems any us, part power. companies that the So almost the right health one only but it than is of wrote -- for adoption that elsewhere. and -- other of business not with by suggest not to of about people the Officer ability AI, will article I fast like especially it's the slower Medical But this an afraid is one of wrote services. each that Forbes But read AI. really the another institutions. deployment and our engines the situation. other generate adoption AI health high right in or the have U.S. to with in economy, to right enough, the the be business usage way, the now, the more By and able is the which revenues because now, implementation from to It provide any I that Chief I are think But

most the experience Corewell, Spectrum from mostly CCS, and the scoring, that is we the U.K. also which calcium we to indications, respect of With these or have the gave right from now, from

cardiovascular one the had them we were in is of I not were ADOPT lot the series osteoporosis. in the bones that that XX% way about chest by the the people solution, TV was with diagnosed, website? if risk. were media U.K., But mainly cardiac was undetected the a would the other diagnosed. And of -- for which with finally, that Israel in you And patients the our the that of in can and that study in the they I in the I we with event one is what the were experience for So the other Beilinson talk the think of published from the results see say previously and

Ran Daniel

Yes.

ability I the You there one number detected cardiac at not and indication patients can an gave diseases of that with gives of that and that see The think website with the take the to published were and have vertebral indication in with this this a we the that do. that Xx was University was scans indicated mentioned structure the to solution bone with was with respect than they patients that Oxford to up that the more identified CT is other compression the there. look were

can attention, more as lot future, go provide can, that institution, way, lot is as we'll what of we the but share, the AI by this a more the the into -- getting and restrictions, privacy the public us under think with the more of share share we we the ability much we will and give more public. we they do InterMountain, relatively and which will with provide I new, the the So because definitely a is is to the we including, the

Operator

Thank Thank today's you for concludes you. call. participating. This conference

disconnect. now may You

Nano-X Imaging (NNOX) 1 Apr 242023 Q4 Earnings call transcript